866777-98-2

Usage

Uses

Used in Oncology:
Mesna is employed as a protective agent in oncology, specifically for the treatment of various cancers. It is used to mitigate the harmful side effects of chemotherapy drugs, thereby improving patient safety and treatment tolerability. The cancers that commonly benefit from mesna's protective properties include ovarian, lung, and breast cancer, as well as lymphomas and leukemia.
Used in Urology:
In urology, mesna serves to protect the bladder from the toxic effects of chemotherapy drugs. By binding to the toxic metabolites, mesna helps prevent bladder damage that can occur during cancer treatment.
Used in Nephrology:
Mesna may also be utilized in nephrology to treat certain kidney conditions. Its protective properties can help shield the kidneys from the harmful effects of chemotherapy drugs, thus preserving renal function.
Used in Radiation Therapy:
During radiation therapy, mesna can be used to protect the bladder from potential damage caused by radiation exposure. Its administration helps ensure that the bladder remains healthy and functional throughout the course of treatment.

Upstream product

• 51594-55-9 (R)-(-)-epichlorohydrin 
• 1184-85-6 N-methylmethane sulphonamide 
• 67843-74-7 (S)-epichlorohydrin 

Downstream Products

• 866933-46-2 Velusetrag 

Relevant academic research and scientific papers

Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT4 receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation

Utilization of Theravance's multivalent approach to drug discovery towards 5-HT4 receptor agonists with a focus on identification of neutral (non-charged at physiological pH) secondary binding groups is described. Optimization of a quinolone-tr

Prokinetic agent for bowel preparation

The invention provides methods of bowel preparation before a diagnostic, surgical or therapeutic procedure, in particular, bowel preparation before a colonoscopy procedure, using a 5-HT4 receptor agonist as a prokinetic agent.

Process for preparing intermediates to 5-HT4 receptor agonist compounds

The invention provides 8-azabicyclo[3.2.1 ]octyl intermediates useful for the preparation of 5-HT4 receptor agonist compounds. The invention also provides processes for the preparation of such useful intermediates.

Crystalline form of a quinolinone-carboxamide compound

The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.

Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.